SOPHiA GENETICS reported third‑quarter 2025 revenue of $19.5 million, a 23% increase from $15.9 million in the same period last year.
The company posted a net IFRS loss of $20.0 million and an adjusted EBITDA loss of $10.2 million, with a diluted loss per share of $0.30, compared with a diluted loss of $0.28 in Q3 2024.
SOPHiA added 31 new customers during the quarter, and the average contract value rose 180% year‑over‑year, underscoring the strength of its land‑and‑expand strategy and the growing demand for its AI‑powered SOPHiA DDM platform.
Adjusted gross margin for Q3 2025 was 73.1%, matching the same figure for Q3 2024, while the company expects full‑year 2025 revenue of $75 million to $77 million and an adjusted EBITDA loss of $39 million to $41 million, moving closer to breakeven by the end of 2026.
Strategic collaborations with AstraZeneca for AI breast‑cancer research and with Myriad Genetics for a global liquid‑biopsy companion diagnostic solution continue to drive growth, while the company focuses on improving operational leverage and cost discipline to achieve profitability.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.